CDC committee votes to resume Johnson & Johnson COVID-19 vaccine despite possible blood clot link
Coronavirus,Coronavirus Vaccine
A Centers for Disease Control and Prevention (CDC) advisory committee is recommending that the Johnson & Johnson COVID-19 vaccine resume rollout, but include new language on the product’s emergency use authorization (EUA) warning remote risks of serious blood clots. The Advisory Committee on Immunization Practices held the vote Friday after the FDA and CDC had recommended a pause in the Johnson & Johnson COVID-19 vaccine rollout last week due to several instances of a rare, severe blood clot amid a backdrop of over 7 million recipients.
The vote was 10 to 4.
One committee member abstained.
AllSides Picks
Bias
Media Bias Alert: DOJ Claims Biden Admin Weaponized Gov’t to ‘Chill Free Speech’ Despite Internal Dissent
Andy Gorel
October 8th, 2026
Red Blue Translator
Anti-vaxxer
Headline Roundup
Record Early Voter Turnout in 2026 Midterms: Which Party Stands to Benefit?
November 3rd, 2026
Recommended Reading
Villain or Hero? How the Left and Right Covered the Lone Holdout Juror in the Lindsay Clancy Trial
Jamie Krstev
November 3rd, 2026
